IRIDEX (NASDAQ:IRIX) Posts Earnings Results, Beats Expectations By $0.05 EPS

IRIDEX (NASDAQ:IRIX) issued its quarterly earnings data on Thursday. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05, Fidelity Earnings reports. IRIDEX had a negative return on equity of 39.42% and a negative net margin of 26.02%. The company had revenue of $10.66 million during the quarter, compared to analysts’ expectations of $10.08 million.

Shares of NASDAQ:IRIX traded down $0.22 during trading on Friday, reaching $1.93. 128,600 shares of the stock were exchanged, compared to its average volume of 43,958. The stock has a 50-day moving average price of $1.88 and a 200-day moving average price of $3.46. The firm has a market cap of $29.30 million, a PE ratio of -1.84 and a beta of 0.80. The company has a current ratio of 3.41, a quick ratio of 2.49 and a debt-to-equity ratio of 0.10. IRIDEX has a 12 month low of $1.50 and a 12 month high of $5.69.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

A number of brokerages have recently issued reports on IRIX. ValuEngine upgraded IRIDEX from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research cut IRIDEX from a “buy” rating to a “hold” rating in a report on Friday, November 1st.


IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.

Further Reading: Is the QQQ ETF safe?

Earnings History for IRIDEX (NASDAQ:IRIX)

Leave a Reply

Your email address will not be published. Required fields are marked *